Ratings by BTIG (Jeet Mukherjee)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/12/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2026 | Innate Pharma S.A. | IPHA | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2026 | Arvinas Inc. | ARVN | Maintain | Buy (Buy) |
|
Details | ||
| 7/24/2026 | Perspective Therapeutics Inc | CATX | Maintain | Buy (Buy) |
|
Details | ||
| 6/29/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2026 | Verastem | VSTM | Maintain | Buy (Buy) |
|
Details | ||
| 5/18/2026 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2026 | Aardvark Therapeutics Inc | AARD | Downgrade | Neutral (Buy) |
6.73 (5.92) |
-12.04% | Details | |
| 5/13/2026 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2026 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2026 | Arvinas Inc. | ARVN | Maintain | Buy (Buy) |
|
Details | ||
| 4/20/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | Ascentage Pharma Group | AAPG | Maintain | Buy (Buy) |
|
Details | ||
| 4/10/2026 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2026 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2026 | Immunitybio Inc | IBRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2026 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2026 | Perspective Therapeutics Inc | CATX | Maintain | Buy (Buy) |
|
Details | ||
| 3/11/2026 | Innate Pharma S.A. | ipha | New Coverage | Buy (N/A) |
1.64 (2.12) |
29.27% | Details | |
| 3/11/2026 | Ascentage Pharma Group | AAPG | New Coverage | Buy (N/A) |
24.49 (16.23) |
-33.73% | Details | |
| 3/11/2026 | Verastem | VSTM | New Coverage | Buy (N/A) |
6.39 (7.61) |
19.09% | Details | |
| 3/11/2026 | Immunitybio Inc | IBRX | New Coverage | Buy (N/A) |
8.01 (7.87) |
-1.75% | Details | |
| 3/11/2026 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
25.33 (30.15) |
19.03% | Details | |
| 3/2/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Buy (N/A) |
|
Details | ||
| 1/15/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Buy (Buy) |
|
Details | ||
| 1/14/2026 | Nurix | NRIX | Maintain | Buy (Buy) |
|
Details | ||
| 1/14/2026 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2026 | Foghorn Therapeutics | FHTX | Maintain | Buy (Buy) |
|
Details | ||
| 1/8/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
17.17 (23.42) |
36.4% | Details | |
| 12/18/2025 | Foghorn Therapeutics | FHTX | New Coverage | Buy (N/A) |
4.64 (5.69) |
22.63% | Details | |
| 12/11/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2025 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Buy (N/A) |
9.87 (6.73) |
-31.81% | Details | |
| 10/30/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2025 | Perspective Therapeutics Inc | CATX | New Coverage | Buy (N/A) |
3.86 (3.10) |
-19.69% | Details | |
| 9/24/2025 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2025 | Monopar Therapeutics | MNPR | New Coverage | Buy (N/A) |
41.48 (117.57) |
183.44% | Details | |
| 5/12/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2025 | Nurix | NRIX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/12/2025 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2024 | Nurix | NRIX | New Coverage | Buy (N/A) |
20.66 (26.04) |
26.04% | Details | |
| 12/10/2024 | Arvinas Inc. | ARVN | New Coverage | Buy (N/A) |
25.08 (9.28) |
-63% | Details | |
| 12/10/2024 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
43.65 (119.05) |
172.74% | Details |
